Xiaosong Ge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaosong Ge has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Dong Hua
School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China; Department of Oncology, Wuxi People's Hospital, Wuxi 214023, China; Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China; Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China
2 shared publications Xiaoli Wang
Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214000, P.R. China
2 shared publicationsYong Mao
Department of Oncology, The Affiliated Hospital of Jiangnan University, Jiangsu
2 shared publications- Yong Mao
Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China
2 shared publications Cailu Shen
Department of Cancer Diagnosis and Treatment Center, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214000, P.R. China
1 shared publicationChen Yang
Department of Cancer Diagnosis and Treatment Center, Affiliated Hospital of Jiangnan University, Wuxi 214122, China
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1936498
Prognostic significance of co-expression of c-MET and EGFR in locally advanced and metastatic gastric cancer: a retrospective cohort study
Objective: Gastric cancer (GC) remains a leading cause of cancer-related mortality globally. While molecular targeted therapies against HER2 and PD-L1 have advanced, the role of receptor tyrosine kinase (RTK) co-activation, specifically between c-MET and EGFR, remains elusive in GC. This study aimed to investigate the correlation between c-MET and EGFR overexpression and clinicopathological features and prognosis in patients with gastric cancer, and to reveal prognostic significance of co-expression of c-MET and EGFR in gastric adenocarcinoma. Methods: The clinicopathological data of 214 Chinese patients with GC were retrospectively analyzed, and the expression level of c-MET and EGFR were detected by immunohistochemistry. χ 2 test was used to investigate associations with clinicopathological features. Kaplan-Meier survival curve and Cox proportional hazards models were employed to analyze the relationship between c-MET, EGFR and co-expression and patient prognosis. Results: The positive expression rates for c-MET and EGFR were 21.96% (47/214) and 68.22% (146/214), respectively. c-MET overexpression was significantly served as an independent predictor of poor OS ( P=0.023 ). Conversely, EGFR expression alone showed no significant prognostic value. Notably, 18.22% (39/214) of cases exhibited co-expression of c-MET and EGFR. Patients with isolated EGFR expression exhibited the most favorable prognosis, while the isolated c-MET expression group had the worst clinical survival. Moreover, patients with c-MET and EGFR co-expression achieved better survival than those with isolated c-MET expression ( P = 0.007 ). Conclusion: c-MET overexpression is a robust prognostic indicator of adverse outcomes in GC. The frequent co-expression of c-MET and EGFR suggests a potential mechanism of RTK cross-talk, warranting further investigation into dual-targeted therapeutic strategies.
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1936498
Open AccessPrognostic significance of co-expression of c-MET and EGFR in locally advanced and metastatic gastric cancer: a retrospective cohort study
Objective: Gastric cancer (GC) remains a leading cause of cancer-related mortality globally. While molecular targeted therapies against HER2 and PD-L1 have advanced, the role of receptor tyrosine kinase (RTK) co-activation, specifically between c-MET and EGFR, remains elusive in GC. This study aimed to investigate the correlation between c-MET and EGFR overexpression and clinicopathological features and prognosis in patients with gastric cancer, and to reveal prognostic significance of co-expression of c-MET and EGFR in gastric adenocarcinoma. Methods: The clinicopathological data of 214 Chinese patients with GC were retrospectively analyzed, and the expression level of c-MET and EGFR were detected by immunohistochemistry. χ 2 test was used to investigate associations with clinicopathological features. Kaplan-Meier survival curve and Cox proportional hazards models were employed to analyze the relationship between c-MET, EGFR and co-expression and patient prognosis. Results: The positive expression rates for c-MET and EGFR were 21.96% (47/214) and 68.22% (146/214), respectively. c-MET overexpression was significantly served as an independent predictor of poor OS ( P=0.023 ). Conversely, EGFR expression alone showed no significant prognostic value. Notably, 18.22% (39/214) of cases exhibited co-expression of c-MET and EGFR. Patients with isolated EGFR expression exhibited the most favorable prognosis, while the isolated c-MET expression group had the worst clinical survival. Moreover, patients with c-MET and EGFR co-expression achieved better survival than those with isolated c-MET expression ( P = 0.007 ). Conclusion: c-MET overexpression is a robust prognostic indicator of adverse outcomes in GC. The frequent co-expression of c-MET and EGFR suggests a potential mechanism of RTK cross-talk, warranting further investigation into dual-targeted therapeutic strategies.
- Open Access
- 4 July 2025
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 23 (3) , 1-10
Treatment patterns and clinical outcomes in Chinese patients with NSCLC with MET alterations resistant to EGFR‑TKI therapy
The present study evaluated therapeutic strategies and clinical outcomes in Chinese patients with mesenchymal‑epithelial transition (MET) alterations in non‑small cell lung cancer (NSCLC) who were progressing on epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI), aiming to address the unmet need of overcoming MET‑driven resistance. A real‑world study was conducted, involving eligible patients with NSCLC treated at Jiangnan University Affiliated Hospital between February 2022 and April 2024. Based on the treatment regimen, patients were categorized into three groups: MET‑TKI combined with EGFR‑TKI, chemotherapy‑based regimen, and other regimens. The primary outcomes were the objective response rate (ORR), time to treatment failure (TTF), post‑progression survival (PPS) and adverse events (AEs). A total of 32 patients were included in the analysis. The MET‑TKI plus EGFR‑TKI group (n=10) achieved the highest ORR at 55.6%, followed by the chemotherapy‑based regimen group (n=15) at 42.9% and the other regimens group (n=7) at 14.3%. The median TTF was 9.5 months for the MET‑TKI plus EGFR‑TKI group, compared with 4.4 and 3.6 months for the chemotherapy‑based and other regimens groups, respectively (P=0.748). Similarly, the median PPS was 14.4 months in the MET‑TKI plus EGFR‑TKI group, compared with 9.4 and 7.0 months in the chemotherapy‑based and other regimens groups, respectively (P=0.733). Treatment‑related AEs varied among the groups, with nausea, peripheral edema and rash being the most common in the MET‑TKI plus EGFR‑TKI group. In conclusion, the combination of MET‑TKI and EGFR‑TKI demonstrates promising benefits in terms of TTF, PPS and ORR, underscoring its potential as a viable treatment option. The modest improvements observed, coupled with the inherent limitations of the present study, emphasize the necessity for further research to optimize treatment strategies and gain a deeper understanding of the long‑term efficacy of combination therapy in addressing MET‑driven resistance to EGFR‑TKI.
- 4 July 2025
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 23 (3) , 1-10
Open AccessTreatment patterns and clinical outcomes in Chinese patients with NSCLC with MET alterations resistant to EGFR‑TKI therapy
The present study evaluated therapeutic strategies and clinical outcomes in Chinese patients with mesenchymal‑epithelial transition (MET) alterations in non‑small cell lung cancer (NSCLC) who were progressing on epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI), aiming to address the unmet need of overcoming MET‑driven resistance. A real‑world study was conducted, involving eligible patients with NSCLC treated at Jiangnan University Affiliated Hospital between February 2022 and April 2024. Based on the treatment regimen, patients were categorized into three groups: MET‑TKI combined with EGFR‑TKI, chemotherapy‑based regimen, and other regimens. The primary outcomes were the objective response rate (ORR), time to treatment failure (TTF), post‑progression survival (PPS) and adverse events (AEs). A total of 32 patients were included in the analysis. The MET‑TKI plus EGFR‑TKI group (n=10) achieved the highest ORR at 55.6%, followed by the chemotherapy‑based regimen group (n=15) at 42.9% and the other regimens group (n=7) at 14.3%. The median TTF was 9.5 months for the MET‑TKI plus EGFR‑TKI group, compared with 4.4 and 3.6 months for the chemotherapy‑based and other regimens groups, respectively (P=0.748). Similarly, the median PPS was 14.4 months in the MET‑TKI plus EGFR‑TKI group, compared with 9.4 and 7.0 months in the chemotherapy‑based and other regimens groups, respectively (P=0.733). Treatment‑related AEs varied among the groups, with nausea, peripheral edema and rash being the most common in the MET‑TKI plus EGFR‑TKI group. In conclusion, the combination of MET‑TKI and EGFR‑TKI demonstrates promising benefits in terms of TTF, PPS and ORR, underscoring its potential as a viable treatment option. The modest improvements observed, coupled with the inherent limitations of the present study, emphasize the necessity for further research to optimize treatment strategies and gain a deeper understanding of the long‑term efficacy of combination therapy in addressing MET‑driven resistance to EGFR‑TKI.
- Open Access
- 1 March 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (2) , 101441
Ce6-GFFY is a novel photosensitizer for colorectal cancer therapy
Photodynamic therapy is an “old” strategy for cancer therapy featuring clinical safety and rapid working, but suitable photosensitizers for colorectal cancer therapy remain lacking. This study synthesized a novel photosensitizer termed Ce6-GFFY based on a self-assembling peptide GFFY and a photo-responsive molecule chlorin e6 (Ce6). Ce6-GFFY forms macroparticles with a diameter of ∼160 nm and possesses a half-life of 10 h, as well as an ideal tumor-targeting ability in mouse models. Ce6-GFFY effectively penetrates cells and generates numerous reactive oxygen species upon 660 nm laser irradiation. The reactive oxygen species promotes the accumulation of cytotoxic T cells and decrease of myeloid-derived suppressor cells in the tumor microenvironment through immunogenic cell death, thus prohibiting the growth of both primary and metastatic tumors after once treatment. This study not only provides a strategy for photosensitizer development but also confirms a promising application of Ce6-GFFY for colorectal cancer therapy.
- 1 March 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (2) , 101441
Open AccessCe6-GFFY is a novel photosensitizer for colorectal cancer therapy
Photodynamic therapy is an “old” strategy for cancer therapy featuring clinical safety and rapid working, but suitable photosensitizers for colorectal cancer therapy remain lacking. This study synthesized a novel photosensitizer termed Ce6-GFFY based on a self-assembling peptide GFFY and a photo-responsive molecule chlorin e6 (Ce6). Ce6-GFFY forms macroparticles with a diameter of ∼160 nm and possesses a half-life of 10 h, as well as an ideal tumor-targeting ability in mouse models. Ce6-GFFY effectively penetrates cells and generates numerous reactive oxygen species upon 660 nm laser irradiation. The reactive oxygen species promotes the accumulation of cytotoxic T cells and decrease of myeloid-derived suppressor cells in the tumor microenvironment through immunogenic cell death, thus prohibiting the growth of both primary and metastatic tumors after once treatment. This study not only provides a strategy for photosensitizer development but also confirms a promising application of Ce6-GFFY for colorectal cancer therapy.
- Open Access
- 1 January 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (1) , 306-327
CircMVP promotes METTL3 activation mediated CTNNB1 m6A modification in the inhibition of colorectal cancer in B7-H3 dependence antitumor immunity
The effect of immunotherapy for colorectal cancer (CRC) is limited due to anti-tumor immunosuppression. Circular RNAs (circRNAs) are also associated with tumor immunity. The aim of this study was to clarify the regulatory relationship between circRNA and anti-tumor immunosuppression in CRC. CircRNAs associated with CRC were identified using bioinformatic analysis and subsequently confirmed in clinical samples using qRT-PCR and in situ hybridization. The expression, clinical relevance, functional significance and clinical properties of circMVP in CRC specimens and cells were evaluated in vitro and in vivo. RNA pull-down, single-cell RNA sequencing, EMSA, RNA immunoprecipitation, chromatin immunoprecipitation, and polysome profiling assay were performed to confirm the underlying mechanism of circRNA. CircMVP (hsa_circ_0000688) expression was increased in CRC and correlated with poor prognosis in CRC patients. Increased circMVP expression activates proliferation, invasion, and tumorigenesis of CRC. In addition, we found that circMVP, by interacting with METTL3, stabilizes its expression in the nucleus and significantly enhances its mediated N6-methyladenosine (m6A) modification. Specifically, circMVP/METTL3 promoted the expression of β-catenin by directly acting on CTNNB1 mRNA. CircMVP/METTL3 further enhanced the expression of B7-H3 through the β-catenin signaling pathway. Notably, inhibition of circMVP expression significantly improved the efficacy of anti-B7-H3 immunotherapy in in vivo and in vitro models. CircMVP mediated CTNNB1 m6A modification by promoting METTL3 activation and inhibited B7-H3-dependent anti-tumor immune response in CRC. In conclusion, circMVP may be a predictor of CRC immune evasion and a potential therapeutic target.
- 1 January 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (1) , 306-327
Open AccessCircMVP promotes METTL3 activation mediated CTNNB1 m6A modification in the inhibition of colorectal cancer in B7-H3 dependence antitumor immunity
The effect of immunotherapy for colorectal cancer (CRC) is limited due to anti-tumor immunosuppression. Circular RNAs (circRNAs) are also associated with tumor immunity. The aim of this study was to clarify the regulatory relationship between circRNA and anti-tumor immunosuppression in CRC. CircRNAs associated with CRC were identified using bioinformatic analysis and subsequently confirmed in clinical samples using qRT-PCR and in situ hybridization. The expression, clinical relevance, functional significance and clinical properties of circMVP in CRC specimens and cells were evaluated in vitro and in vivo. RNA pull-down, single-cell RNA sequencing, EMSA, RNA immunoprecipitation, chromatin immunoprecipitation, and polysome profiling assay were performed to confirm the underlying mechanism of circRNA. CircMVP (hsa_circ_0000688) expression was increased in CRC and correlated with poor prognosis in CRC patients. Increased circMVP expression activates proliferation, invasion, and tumorigenesis of CRC. In addition, we found that circMVP, by interacting with METTL3, stabilizes its expression in the nucleus and significantly enhances its mediated N6-methyladenosine (m6A) modification. Specifically, circMVP/METTL3 promoted the expression of β-catenin by directly acting on CTNNB1 mRNA. CircMVP/METTL3 further enhanced the expression of B7-H3 through the β-catenin signaling pathway. Notably, inhibition of circMVP expression significantly improved the efficacy of anti-B7-H3 immunotherapy in in vivo and in vitro models. CircMVP mediated CTNNB1 m6A modification by promoting METTL3 activation and inhibited B7-H3-dependent anti-tumor immune response in CRC. In conclusion, circMVP may be a predictor of CRC immune evasion and a potential therapeutic target.
- Open Access
- 26 March 2018
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 48 (5) , 480-484
Long non-coding RNA expression profiles reveals AK098783 is a biomarker to predict poor prognosis in patients with colorectal cancer
Long non-coding RNAs (lncRNAs) have essential regulatory function, yet their roles in colorectal cancer (CRC) are not well understood. Microarray was applied to detect lncRNAs expression profiles in tumor tissues, liver metastasis and paired adjacent normal tissues of CRC. And using RT-PCR to verify chip results. A total of 10 680 lncRNAs demonstrated differential expressions (fold change ≥2) between tumor tissues and adjacent normal tissues; furthermore there were 2970 lncRNAs, which showed different expression level between CRC tissues with liver metastasis and adjacent normal tissues. Especially, lncRNA-AK098783 expression level was frequently higher in cancerous tissues than corresponding noncancerous tissue. Higher AK098783 expression was significantly correlated with shortened overall survival (P < 0.001) and distant metastasis (P < 0.001). Our results suggest that AK098783 is involved in distant metastasis and dramatically associated with poor prognosis in patients with CRC.
- 26 March 2018
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 48 (5) , 480-484
Open AccessLong non-coding RNA expression profiles reveals AK098783 is a biomarker to predict poor prognosis in patients with colorectal cancer
Long non-coding RNAs (lncRNAs) have essential regulatory function, yet their roles in colorectal cancer (CRC) are not well understood. Microarray was applied to detect lncRNAs expression profiles in tumor tissues, liver metastasis and paired adjacent normal tissues of CRC. And using RT-PCR to verify chip results. A total of 10 680 lncRNAs demonstrated differential expressions (fold change ≥2) between tumor tissues and adjacent normal tissues; furthermore there were 2970 lncRNAs, which showed different expression level between CRC tissues with liver metastasis and adjacent normal tissues. Especially, lncRNA-AK098783 expression level was frequently higher in cancerous tissues than corresponding noncancerous tissue. Higher AK098783 expression was significantly correlated with shortened overall survival (P < 0.001) and distant metastasis (P < 0.001). Our results suggest that AK098783 is involved in distant metastasis and dramatically associated with poor prognosis in patients with CRC.
- Open Access
- 1 January 2018
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 17
MicroRNA-142-3p Promotes Cellular Invasion of Colorectal Cancer Cells by Activation of RAC1
Colorectal cancer has been proved more difficult to treat owing to potently malignant metastasis. The present study was aimed to explore the functional role of miR-142-3p in cell migration and invasion of colorectal cancer cells, as well as its underlying mechanism. Expressions of miR-142-3p were analyzed in colorectal cancer tissues and cell lines. Ras-related C3 botulinum toxin substrate 1 (RAC1) was predicted as a target of miR-142-3p using software and network resources. SW480 cells were transfected with miR-142-3p expression plasmid and miR-142-3p silencer plasmid, and the expression of RAC1 and the cellular invasion were measured. In colorectal cancer cells transfected with miR-142-3p expression plasmid, RAC1 was specifically upregulated and invasiveness of cells was downregulated. Moreover, RAC1 was significantly associated with tumor stage (P = .029) and tumor metastasis (P = .012). miR-142-3p promotes cellular invasion in colorectal cancer cells by activating RAC1. Thereby, miR-142-3p is a potential candidate for molecular targeted therapy of colorectal cancer.
- 1 January 2018
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 17
Open AccessMicroRNA-142-3p Promotes Cellular Invasion of Colorectal Cancer Cells by Activation of RAC1
Colorectal cancer has been proved more difficult to treat owing to potently malignant metastasis. The present study was aimed to explore the functional role of miR-142-3p in cell migration and invasion of colorectal cancer cells, as well as its underlying mechanism. Expressions of miR-142-3p were analyzed in colorectal cancer tissues and cell lines. Ras-related C3 botulinum toxin substrate 1 (RAC1) was predicted as a target of miR-142-3p using software and network resources. SW480 cells were transfected with miR-142-3p expression plasmid and miR-142-3p silencer plasmid, and the expression of RAC1 and the cellular invasion were measured. In colorectal cancer cells transfected with miR-142-3p expression plasmid, RAC1 was specifically upregulated and invasiveness of cells was downregulated. Moreover, RAC1 was significantly associated with tumor stage (P = .029) and tumor metastasis (P = .012). miR-142-3p promotes cellular invasion in colorectal cancer cells by activating RAC1. Thereby, miR-142-3p is a potential candidate for molecular targeted therapy of colorectal cancer.
- 1 October 2017
- Published by Elsevier in Pathology - Research and Practice
- Vol. 213 (10) , 1296-1301
CD61+ and CAF+ were found to be good prognosis factors for invasive breast cancer patients
- 1 October 2017
- Published by Elsevier in Pathology - Research and Practice
- Vol. 213 (10) , 1296-1301
CD61+ and CAF+ were found to be good prognosis factors for invasive breast cancer patients
- 14 January 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (10) , 7760-7764
Identification of different tumor states in nasopharyngeal cancer using surface-enhanced Raman spectroscopy combined with Lasso-PLS-DA algorithm
Identification of different states in cancer is of vital importance for cancer treatment and management.
- 14 January 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (10) , 7760-7764
Identification of different tumor states in nasopharyngeal cancer using surface-enhanced Raman spectroscopy combined with Lasso-PLS-DA algorithm
Identification of different states in cancer is of vital importance for cancer treatment and management.